Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

Core Insights - Terns Pharmaceuticals, Inc. has appointed Andrew Gengos as the new Chief Financial Officer, effective immediately, bringing 25 years of leadership experience in the biotech sector [1][2][3] Company Overview - Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates targeting serious diseases, including oncology and obesity [4] - The company's pipeline includes three clinical-stage development programs: an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-β agonist, along with a preclinical GIPR modulator discovery effort [4] Leadership and Experience - Andrew Gengos has a strong background in finance and corporate strategy, having previously served as CFO of Athira Pharma and held leadership roles at Cyteir Therapeutics, ImmunoCellular Therapeutics, and Neuraltus Pharmaceuticals [3] - Gengos has experience in leading teams in the life sciences and biotechnology industry, with a notable tenure at Amgen as Vice President of Strategy and Corporate Development [3]